SIK2 inhibitor SIC-19 enhances the sensitivity of PARP inhibitors in triple-negative breast cancers and pancreatic cancers
These results underscore the potential of combining PARP inhibitors in combination with SIK2 inhibitors as a novel therapeutic approach to increase PARP inhibition's effectiveness in treating TNBC and PC. This innovative combination therapy represents a promising approach for overcoming resistance mechanisms and improving the outcomes for patients with these challenging malignancies.
Authors
- Jia Zhou (ORCID: https://orcid.org/0000-0002-6277-6491)
- M Zhu
- Qian Li (ORCID: https://orcid.org/0000-0003-3328-1147)
- Shuai Zhu (ORCID: https://orcid.org/0000-0001-8786-4941)
- Fang Wang (ORCID: https://orcid.org/0000-0001-7729-5669)
Institutions
- Soochow University (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2025-01-01
- DOI
- https://doi.org/10.32604/or.2025.062539
- Citations
- 3
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 3.14